Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 +5.22 (+3.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
71 72 Next >
AbbVie's Blockbuster Is Falling Fast. Time to Sell?
Rapidly declining Humira sales weren't the only disappointment AbbVie shared in its first-quarter earnings report. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
Don't let the temporary headwinds for two of these stocks fool you. 
Via The Motley Fool
AbbVie (ABBV) Q1 2023 Earnings Call Transcript
ABBV earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Why AbbVie Stock Is Crashing Today
AbbVie's 2023 Q1 report isn't sitting well with shareholders today. 
Via The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
Via Benzinga
Why AbbVie Shares Are Trading Lower Today
AbbVie Inc (NYSE: ABBV) has reported Q1 adjusted EPS of $2.46 
Via Benzinga
AbbVie Stock Crumbles As Humira Biosimilars Take A 25% Cut
The Humira downfall wasn't as steep an analysts expected, but AbbVie stock tumbled early Thursday. 
Via Investor's Business Daily
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies
Check out these compelling opportunities. 
Via The Motley Fool
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Dow, Nasdaq Hold Triple-Digit Gains
The Dow Jones Industrial Average and Nasdaq Composite are both up triple-digits, despite this morning's GDP data which showed less economic growth than expected. 
Via Talk Markets
1 Dividend Stock to Buy Hand Over Fist in May and 1 to Avoid
There's more to picking worthy dividend stocks than the forward yield. 
Via The Motley Fool
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Making Surprising Moves in Monday Session
Via Investor Brand Network
Price Over Earnings Overview: AbbVie
Via Benzinga
3 Stocks You Can Keep Forever
Three solid profitable companies that are growing their businesses and their dividends. 
Via The Motley Fool
Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase
From Hagens Berman Sobol Shapiro LLP
Via Business Wire
A Rotation Into Defensive Stocks? Market Strength Seen In Consumer Defensive And Healthcare On Tuesday
The U.S. stock market is seeing some modest selling on Tuesday morning after a series of largely uneventful sessions last week. Two hours into the trading day, the S&P 500 was down around 0.75% and the... 
Via Benzinga
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
3 Reasons Why I Regret Selling AbbVie
Having the knowledge to stay steady in your convictions can be a game changer. 
Via The Motley Fool
3 Winning Stocks to Buy No Matter What the Market Is Doing
The long-term picture for these stocks remains bright. 
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
You'll want to hold on to these top stocks for the long term. 
Via The Motley Fool
Looking Into The JEPI ETF Hype: What Is This ETF?
There's an ETF that has been the talk of the town lately. I'm not talking about Charles Schwab’s SCHD. This is about the premium income ETF JEPI from JPMorgan Chase. This high yielding ETF has garnered... 
Via Talk Markets
3 Top Dividend Kings to Buy for the Long Haul
These healthcare stocks all have above-average dividends. 
Via The Motley Fool
AbbVie's Preventive Treatment For Migraine Meets Primary Goal In Patients With Failed Medications
AbbVie Inc (NYSE: ABBV) announced data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of... 
Via Benzinga
Citigroup, Dell And 2 Other Stocks Insiders Are Selling
The S&P 500 closed almost flat on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?
Merck's move into immunology is a risky proposition. 
Via The Motley Fool
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.